Phase 2 × Terminated × Leukemia, Lymphocytic, Chronic, B-Cell × Clear all Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
Phase 2 Terminated
5 enrolled 11 charts
TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
Phase 2 Terminated
12 enrolled 10 charts
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Phase 2 Terminated
30 enrolled
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
Phase 2 Terminated
4 enrolled 7 charts
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2 Terminated
31 enrolled 18 charts
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Phase 2 Terminated
150 enrolled
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
Phase 2 Terminated
2 enrolled 6 charts
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Phase 2 Terminated
4 enrolled 8 charts
Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma
Phase 2 Terminated
30 enrolled
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Phase 2 Terminated
9 enrolled 11 charts
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Phase 2 Terminated
55 enrolled
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 Terminated
3 enrolled 11 charts
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
Phase 2 Terminated
5 enrolled
Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
Phase 2 Terminated
51 enrolled 12 charts
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Terminated
20 enrolled 8 charts
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma
Phase 2 Terminated
34 enrolled 2 charts
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
Phase 2 Terminated
41 enrolled 4 charts
Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia
Phase 2 Terminated
59 enrolled 8 charts
Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma
Phase 2 Terminated
6 enrolled 7 charts
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
Phase 2 Terminated
31 enrolled 10 charts
A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304
Phase 2 Terminated
116 enrolled 11 charts
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
Phase 2 Terminated
1 enrolled 8 charts
Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Terminated
9 enrolled 9 charts
Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
Phase 2 Terminated
51 enrolled
VZCLLPI0146
Phase 2 Terminated
5 enrolled 10 charts
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Terminated
1 enrolled 6 charts
Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 Terminated
3 enrolled 12 charts
Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis
Phase 2 Terminated
12 enrolled 8 charts
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies
Phase 2 Terminated
326 enrolled 26 charts
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Phase 2 Terminated
3 enrolled 17 charts
DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia
Phase 2 Terminated
26 enrolled
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
Phase 2 Terminated
66 enrolled 14 charts
Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL
Phase 2 Terminated
10 enrolled
Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
Phase 2 Terminated
39 enrolled 10 charts
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Phase 2 Terminated
4 enrolled 13 charts
Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)
Phase 2 Terminated
18 enrolled 10 charts
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
Phase 2 Terminated
6 enrolled 8 charts
Post Transplant Donor Lymphocyte Infusion
Phase 2 Terminated
57 enrolled 13 charts
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
Phase 2 Terminated
1 enrolled 4 charts
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
Phase 2 Terminated
10 enrolled 10 charts
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Phase 2 Terminated
4 enrolled 4 charts
Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
Phase 2 Terminated
102 enrolled 8 charts
Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)
Phase 2 Terminated
2 enrolled 2 charts
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Phase 2 Terminated
5 enrolled 10 charts
R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
Phase 2 Terminated
25 enrolled
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Phase 2 Terminated
12 enrolled 12 charts
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
Phase 2 Terminated
12 enrolled 7 charts
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
Phase 2 Terminated
200 enrolled 11 charts
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
Phase 2 Terminated
3 enrolled 10 charts
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Phase 2 Terminated
13 enrolled 24 charts